WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years.

GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and access to life-saving interventions.i As opioid overdose remains a significant global public health challenge, Emergent is focused on empowering people with the information and tools needed to act in the event of an opioid overdose emergency.

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMERGENT BIOSOLUTIONS INC. (EBS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discus.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMERGENT BIOSOLUTIONS INC. (EBS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 5, 2026, Emergent reported resu.

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

LOS ANGELES--(BUSINESS WIRE)---- $EBS--EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law.

Emergent BioSolutions reported approximately $97 million in adjusted EBITDA for the quarter. The same period included a $191.3 million non-cash NARCAN impairment.

Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue -- above its own prior guidance -- while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations. Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue -- above its own prior guidance -- while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations.